EasyM

05/15/2026

The Evolving Role of MRD in Multiple Myeloma Care 🎯

A recent review by Landgren et al. (2026) describes how Minimal Residual Disease (MRD) is transitioning from a research metric into a clinical tool for informing treatment strategies and drug approvals.

Three Key Observations:

1. Regulatory Milestones: The FDA has recognized MRD as an "early endpoint" for accelerated approval. This regulatory shift aims to bring promising therapies to patients faster by evaluating disease clearance at the molecular level (10-5 or 10-6).

2. Response Adapted Strategies: Data from clinical trials, including PERSEUS, MIDAS, and ADVANCE, demonstrate the feasibility of using MRD to personalize care. Research indicates that for some patients, sustained MRD negativity may allow for discussions regarding treatment de-escalation (such as modifying maintenance or transplant timing), while persistent MRD may suggest a need for intensified therapy.

3. Advances in Monitoring: The field is exploring high-sensitivity blood-based MRD tools (such as mass spectrometry and ctDNA). These emerging "global" tests aim to provide non-invasive monitoring of the entire body.

The Bottom Line: We are moving toward personalized care and MRD assessment could help provide a "compass" that can help your healthcare team tailor treatment based on your specific response.

📖 Read the full scientific review: https://doi.org/10.1053/j.seminhematol.2026.01.002

05/13/2026

MRD Response: Why Durability Matters More Than Speed

📃New data from the NICHE study (1,048 patients) suggests that when it comes to Minimal Residual Disease (MRD), the speed of your response may be less important than its durability.

Key Findings:

-The "Late + Durable" Advantage: Patients who took longer than 6 months to reach their best response often had better long-term survival than "early responders."
- Duration is Key: Maintaining a stable response for 36+ months was a stronger predictor of success than hitting "MRD Negative" early on.
- Stable is Successful: Even patients who remained "persistent MRD positive" saw excellent outcomes if their disease burden stayed low and stable over time.
- Overcoming High Risk: A durable response helped "cancel out" adverse features, such as high-risk cytogenetics or skipping a transplant.

This study highlights the value of longitudinal monitoring, tracking your personal trends over years, not just months. Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/ijc.70465

Follow along for the latest updates in MRD research 📣

05/08/2026

Standard vs. MRD Monitoring: A Deep Dive into M-Protein Testing 🩸

Standard Laboratory Monitoring (SPEP/IFE):

- Clinical standards used to measure monoclonal protein (M-protein) levels.
- These tests analyze the overall distribution of proteins to identify an M-protein "spike."
- Effective at identifying high levels of disease, these tests have a defined "Limit of Detection." Once protein levels decrease below this threshold, they may be unable to distinguish the M-protein from normal, healthy proteins.
- A "not detected" result indicates a significant clinical response, though it does not always confirm the absence of disease at a molecular level.

Minimal Residual Disease Monitoring (Mass Spectrometry):

- Used in specific clinical contexts to achieve higher levels of sensitivity.
- This approach identifies the unique "fingerprint" of a patient’s specific M-protein.
- By focusing on this specific sequence, the laboratory can distinguish the M-protein from background proteins, allowing for the identification of residual disease even when levels are below the detection limit of conventional methods.

Follow along to learn more about MRD in MM 💡

05/06/2026

Understanding Blood Based MRD Monitoring in Multiple Myeloma 🩸


Check out this HealthTree for Multiple Myeloma Foundation webinar recording featuring Dr. Benjamin Derman 👇

Dr. Derman provides an excellent breakdown of blood based minimal residual disease (MRD) testing in multiple myeloma (MM). Watch the recording to get a better understanding of how these non-invasive alternatives are evolving in MM care.

Webinar content:
- A clear explanation of how blood based testing works to monitor MRD in MM.
- Insights into the role of these tools in assessing treatment response and molecular clearance.
- Practical guidance on how to discuss these tools with your healthcare team.

Link: https://healthtree.org/myeloma/community/events/apr26-myeloma-mrd-testing?utm_source=intercom&utm_medium=email&utm_campaign=followuprecording&utm_content=general

05/01/2026

Three Pillars to MRD Monitoring in Myeloma 💪

Clinicians use three complementary methods to track disease response:

1. Mass Spectrometry: Tracks the unique M-protein "fingerprint" in the blood.

2. NGS/NGF: Uses bone marrow biopsies to directly count residual cancer cells.

3. PET/MRI: Uses advanced imaging to visualize where myeloma is active or located in the body.

Why it matters: These approaches are often used together to provide a holistic view of the disease.

Talk to your healthcare team about which monitoring approach is right for your clinical journey.

04/29/2026

The "Baseline" Sample: Don’t Miss the Window for MRD Tracking

If you are considering advanced minimal residual disease (MRD) monitoring for Multiple Myeloma, there is a critical first step for many technologies: The Baseline.

Why it’s essential:

Newer monitoring technologies work by identifying your cancer’s unique molecular "fingerprint." To track this fingerprint at ultra-sensitive levels later, the lab must first "map" it while your levels are still detectable (usually at diagnosis or before a new treatment).

Share this to your networks to help others learn about the importance of baselines 💡

04/22/2026

In case you missed it last week 📰

The University of Waterloo recently published a news article on the development of EasyM, a blood based minimal residual disease (MRD) test for Multiple Myeloma (MM) 🩸

Key Takeaway Points:

- Sensitivity & Specificity: Research indicates that EasyM can detect the unique M-protein "fingerprint" even when traditional methods cannot.

- Observation Windows: In clinical evaluations, blood-based monitoring identified rising M-protein levels up to 11 months earlier than conventional methods.

- Accessibility: Following the Ministry of Health provisional license, this non-invasive MRD monitoring tool is available for clinical use in Canada.

Read the full article here: https://uwaterloo.ca/news/diagnosing-cancer-drop-blood

04/21/2026

What a week last week!

As part of our National Medical Laboratory Week celebrations, we were thrilled to host our partners from Evosep, Promega, and Thermo Fisher Scientific for a series of impactful Lunch & Learns last week.

Key takeaways from the week:

Patient-Centered Care: Understanding how lab precision directly impacts patient outcomes.
Companion Diagnostics: Exploring the future of personalized medicine and targeted therapy.
Best Practices: Deep dives into clinical lab quality to ensure reliability.

A huge thank you to our guest speakers for sharing their expertise and helping us sharpen our focus on the patients we serve.

04/17/2026

We’re proud to see our work featured by the University of Waterloo 🧡

A recent article highlights how EasyM is helping transform multiple myeloma care, making it possible to detect and monitor cancer with a simple blood test instead of invasive bone marrow biopsies.

Our technology uses each patient’s unique M-protein “fingerprint” to track disease progression and can detect relapse 2 to 11 months earlier than traditional methods.

This recognition reflects more than a decade of research, collaboration, and a shared goal: improving patient care through innovation.

The article also highlights that EasyM is available for Canadian patients through a provisional licence from the Ontario Ministry of Health.

Read the full story here: https://lnkd.in/evvmNZai

Advances in medical research are reshaping how blood cancers are diagnosed and monitored.

Rapid Novor, a Waterloo‑based company co‑founded by University of Waterloo professor Dr. Bin Ma, is helping transform care for myeloma, a blood cancer affecting the bone marrow. Traditionally, patients undergo repeated and invasive bone marrow biopsies to diagnose the disease and monitor treatment.

Rapid Novor’s EasyM test offers a non‑invasive alternative. Using a simple blood draw, this highly sensitive test detects and measures M‑protein, a key myeloma biomarker, providing clinicians with a safer and more accessible option for ongoing disease monitoring.

More: https://uwaterloo.ca/news/diagnosing-cancer-drop-blood |

04/13/2026

Celebrating the experts behind the answers 🔬✨

It’s National Medical Laboratory Week, and we are incredibly proud to celebrate our medical laboratory staff who are the "engine room" of EasyM.

We have a fun-filled week of activities planned to celebrate our incredible team and the vital work they do for Multiple Myeloma patients.

👀 Keep an eye on our feed all week for updates!

To all the lab tech superstars, pathologists, and scientists: Thank you for your precision, your passion, and your persistence. Happy !

04/10/2026

One day. One goal: Advancing the future of MRD 💪

We will be on the ground tomorrow in Miami for the myeloma MRD meeting! With a packed schedule, it’s going to be a milestone day for the community.

At EasyM, we are passionate about making MRD monitoring more accessible and patient-friendly through blood-based clonotypic mass spectrometry.

📩 DM us to set up a quick chat, we’d love to talk all things MRD with you!